ArticleCell reports. Medicine2021
Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis.
Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Metabolomics in Multiple Sclerosis: Advances, Challenges, and Clinical Perspectives-A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Perturbations in gut microbiota composition in patients with autoimmune neurological diseases: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review.International journal of environmental research and public health · 2023Pooled it
- The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis.Frontiers in neuroscience · 2023Pooled it
- Functional Training Mitigates Reduced Circulating Indole-3-Lactate Levels in Persons With Relapsing-Remitting Multiple Sclerosis.Acta physiologica (Oxford, England) · 2026Trial
- A randomized cross-over trial of prebiotics and probiotics in multiple sclerosis: Trial feasibility, supplement tolerability and symptom abatement.Multiple sclerosis and related disorders · 2024Trial
- The Gut Microbiome in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026Review
- Integrated multi-omics analysis identifies microbial and metabolic signatures and drivers of CNS autoimmunity.mSystems · 2026Article
- Integrated multi-omics analysis identifies microbial and metabolic signatures and drivers of CNS autoimmunity.bioRxiv : the preprint server for biology · 2026Article
- Plasma untargeted metabolomics reveals metabolic signatures associated with epilepsy and anti-seizure medication responsiveness.Frontiers in molecular biosciences · 2026Article
- Novel cross-feeding human gut microbes metabolizing tryptophan to indole-3-propionate.Gut microbes · 2025Article
- Linking Nutrients to Multiple Sclerosis Pathogenesis: Biological Evidence and Clinical Implications.Nutrients · 2025Review
- Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets.Molecular biomedicine · 2025Review
- Butyrate enhances CD56Genes and immunity · 2025Article
- Longitudinal alterations of gut mycobiota during 2 years after COVID-19 and its correlation with pulmonary sequela.Microbiology spectrum · 2025Article
- Metabolomic Associations With Fatigue and Physical Function in Children With Cancer: A Pilot Study.Biological research for nursing · 2025Article
- Evaluating the impact of gut microbiota, circulating cytokines and plasma metabolites on febrile seizure risk in Mendelian randomization study.Scientific reports · 2025Article
- Metabolic and lipid alterations in multiple sclerosis linked to disease severity.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Unveiling the Important Role of Gut Microbiota and Diet in Multiple Sclerosis.Brain sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is an immune-mediated disease whose precise etiology is unknown. Several studies found alterations in the microbiome of individuals with MS, but the mechanism by which it may affect MS is poorly understood. Here we analyze the microbiome of 129 individuals with MS and find that they harbor distinct microbial patterns compared with controls. To study the functional consequences of these differences, we measure levels of 1,251 serum metabolites in a subgroup of subjects and unravel a distinct metabolite signature that separates affected individuals from controls nearly perfectly (AUC = 0.97). Individuals with MS are found to be depleted in butyrate-producing bacteria and in bacteria that produce indolelactate, an intermediate in generation of the potent neuroprotective antioxidant indolepropionate, which we found to be lower in their serum. We identify microbial and metabolite candidates that may contribute to MS and should be explored further for their causal role and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.